Soleno Therapeutics (NASDAQ:SLNO) Shares Down 7.2% – Here’s Why

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) were down 7.2% during trading on Friday . The company traded as low as $30.03 and last traded at $29.5780. Approximately 201,076 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 1,588,168 shares. The stock had previously closed at $31.86.

More Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Negative Sentiment: Multiple law firms have filed or publicized class-action claims alleging investors were harmed by Soleno’s statements around its DCCR program; these filings heighten litigation risk and market uncertainty, pressuring the stock. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Multiple plaintiff firms (Rosen, Faruqi & Faruqi, Bernstein Liebhard, Kessler Topaz, Robbins Geller, et al.) are soliciting lead plaintiffs and reminding investors of the May 5, 2026 deadline — increased media/legal attention can prompt selling and weigh on sentiment. SLNO INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
• Negative Sentiment: The alleged catalyst cited across filings is the company’s November 5, 2025 disclosure about disappointing information and launch disruptions for DCCR (VYKAT™ XR); plaintiffs claim misstatements or omissions regarding the drug’s safety/timeline, which could lead to damages, regulatory scrutiny, and distraction from commercial execution. SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit — The Gross Law Firm

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a report on Tuesday, January 13th. Zacks Research cut Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Wells Fargo & Company dropped their price objective on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Finally, HC Wainwright cut their price objective on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $102.60.

Soleno Therapeutics Price Performance

The company’s 50-day moving average price is $38.77 and its two-hundred day moving average price is $48.95. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. The company has a market capitalization of $1.55 billion, a P/E ratio of 129.77 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. As a group, sell-side analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Hedge Funds Weigh In On Soleno Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after purchasing an additional 189 shares during the period. Goldman Sachs Group Inc. boosted its stake in Soleno Therapeutics by 50.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company’s stock valued at $45,236,000 after purchasing an additional 213,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Soleno Therapeutics by 48.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock valued at $2,909,000 after buying an additional 13,211 shares in the last quarter. Creative Planning acquired a new position in Soleno Therapeutics in the 2nd quarter valued at $338,000. Finally, Handelsbanken Fonder AB bought a new position in Soleno Therapeutics during the 2nd quarter worth $871,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.